Biosimilars Market
Biosimilar Market Research Report Information by Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Bevacizumab, Trastuzumab, Ustekinumab, Tocilizumab, Aflibercept, Dupilumab, Denosumab, Others), Insulin, Granulocyte Colony- stimulating Factor, Erythropoietin, Recombinant Human Growth Hormone, Etanercept, Follitropin, Teriparatide, Anticoagulants, Others), by Application (Oncology (Breast Cancer, Lung Cancer, Prostate Cancer, Leukemia, Bladder Cancer, Colorectal Cancer, Others), Autoimmune Diseases, Infectious Diseases, Blood Disorders, Others), by Route of Administration (Subcutaneous and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies) and Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa) - Forecast till 2035
Biosimilar Market Overview
The Biosimilar Market was valued at USD 32.72 billion in 2024. The Biosimilar Market industry is projected to grow from USD 37.76 billion in 2025 to USD 134.83 billion by 2035, exhibiting a compound annual growth rate (C..